Literature DB >> 23795903

Characteristics of major Escherichia coli reductases involved in aerobic nitro and azo reduction.

C Mercier1, V Chalansonnet, S Orenga, C Gilbert.   

Abstract

AIMS: Escherichia coli is able to reduce azo compounds such as methyl red (MR) and nitro compounds such as 7-nitrocoumarin-3-carboxylic acid (7NCCA). The aim of this study was to clarify the specificity of the major E. coli reductases. METHODS AND
RESULTS: Enzymatic assays with pure enzymes obtained after cloning, overproduction and purification under native or denaturing conditions were performed on three enzymes: AzoR, NfsA and NfsB. Their dependence on putative cofactors such as flavin mononucleotide (FMN), NADH and NADPH was studied as well as the reductase capacity of E. coli mutants depleted for one, two or three of the corresponding genes.
CONCLUSIONS: AzoR was able to reduce both MR and 7NCCA, whereas NfsA and NfsB could only reduce the nitro compound. AzoR and NfsB were strictly FMN dependent in contrast to NfsA. At a low oxygen concentration, the three proteins were not mandatory for azo reduction and nitro reduction, but in optimal aerobic conditions, azoR was essential for MR reduction, and an nfsA/nfsB combination was important for 7NCCA reduction. Overexpression of azoR gene was able to compensate for the loss of nfsA and nfsB under aerobic conditions. SIGNIFICANCE AND IMPACT OF STUDY: These data provide new insights into the substrate specificity of major E. coli nitroreductases and demonstrate that oxygen is an important parameter to take into account in studies of nitroreductase activity.
© 2013 The Society for Applied Microbiology.

Entities:  

Keywords:  AzoR; Escherichia coli; NfsA; NfsB; aerobic; anaerobic; azoreductase; nitroreductase

Mesh:

Substances:

Year:  2013        PMID: 23795903     DOI: 10.1111/jam.12294

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  7 in total

Review 1.  Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?

Authors:  Hollie I Swanson
Journal:  Drug Metab Dispos       Date:  2015-08-10       Impact factor: 3.922

2.  Rapid evaluation of the substrate specificity of 3-nitrobenzoic acid dioxygenase MnbAB via colorimetric detection using Saltzman reagent.

Authors:  Hiroya Tomita; Yohei Katsuyama; Yasuo Ohnishi
Journal:  J Ind Microbiol Biotechnol       Date:  2021-12-23       Impact factor: 4.258

3.  An in vitro deletion in ribE encoding lumazine synthase contributes to nitrofurantoin resistance in Escherichia coli.

Authors:  Jascha Vervoort; Basil Britto Xavier; Andrew Stewardson; Samuel Coenen; Maciek Godycki-Cwirko; Niels Adriaenssens; Anna Kowalczyk; Christine Lammens; Stephan Harbarth; Herman Goossens; Surbhi Malhotra-Kumar
Journal:  Antimicrob Agents Chemother       Date:  2014-09-22       Impact factor: 5.191

4.  Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging.

Authors:  Anzhelika G Vorobyeva; Michael Stanton; Aurélien Godinat; Kjetil B Lund; Grigory G Karateev; Kevin P Francis; Elizabeth Allen; Juri G Gelovani; Emmet McCormack; Mark Tangney; Elena A Dubikovskaya
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

5.  Identification of Enterococcus faecalis enzymes with azoreductases and/or nitroreductase activity.

Authors:  Valérie Chalansonnet; Claire Mercier; Sylvain Orenga; Christophe Gilbert
Journal:  BMC Microbiol       Date:  2017-05-25       Impact factor: 3.605

6.  Azoreductase activity of dye-decolorizing bacteria isolated from the human gut microbiota.

Authors:  Sara A Zahran; Marwa Ali-Tammam; Abdelgawad M Hashem; Ramy K Aziz; Amal E Ali
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

7.  Bayesian Modeling and Intrabacterial Drug Metabolism Applied to Drug-Resistant Staphylococcus aureus.

Authors:  Jimmy S Patel; Javiera Norambuena; Hassan Al-Tameemi; Yong-Mo Ahn; Alexander L Perryman; Xin Wang; Samer S Daher; James Occi; Riccardo Russo; Steven Park; Matthew Zimmerman; Hsin-Pin Ho; David S Perlin; Véronique Dartois; Sean Ekins; Pradeep Kumar; Nancy Connell; Jeffrey M Boyd; Joel S Freundlich
Journal:  ACS Infect Dis       Date:  2021-08-03       Impact factor: 5.578

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.